Filtered By:
Condition: Hypertension
Management: Centers for Disease Control and Prevention (CDC)
Countries: Canada Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2 results found since Jan 2013.

The 5 Best Ways to Control High Cholesterol, According to People With the Condition
There are a variety of factors that influence cardiovascular risk—but cholesterol is one of the first things that doctors pay attention to. Having high levels of low-density lipoprotein (LDL) cholesterol is “definitely a variable we try to manage, because it’s been shown to be problematic for heart health,” says Dr. Adriana Quinones-Camacho, a cardiologist at NYU Langone Health. Though it’s often called the “bad” kind of cholesterol, LDL cholesterol makes up most of your body’s cholesterol stores. That means it’s not a villain on its own, but when levels start creeping ...
Source: TIME: Health - January 18, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news